Solventum Corporation $SOLV Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. lowered its holdings in Solventum Corporation (NYSE:SOLV) by 15.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,056 shares of the company’s stock after selling 200 shares during the quarter. Harbour Investments Inc.’s holdings in Solventum were worth $80,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Independent Franchise Partners LLP lifted its holdings in Solventum by 263.1% in the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after acquiring an additional 4,217,570 shares during the period. Davis Selected Advisers lifted its holdings in Solventum by 0.8% in the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock valued at $402,110,000 after acquiring an additional 41,524 shares during the period. Boston Partners increased its position in shares of Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after buying an additional 1,691,565 shares in the last quarter. Northern Trust Corp increased its position in shares of Solventum by 3.3% in the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after buying an additional 58,373 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Solventum by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock valued at $89,268,000 after buying an additional 24,762 shares in the last quarter.

Solventum Trading Down 0.6%

Solventum stock opened at $72.30 on Friday. The stock has a market cap of $12.54 billion, a PE ratio of 33.47, a P/E/G ratio of 2.96 and a beta of 0.50. The stock has a 50-day moving average price of $72.62 and a 200 day moving average price of $72.07. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SOLV shares. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a research report on Wednesday, October 8th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research report on Tuesday, July 1st. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. Piper Sandler restated an “overweight” rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, UBS Group started coverage on Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.